Classic Hodgkin Lymphoma — Trials

Classic Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

114 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 41
Recruiting: 17
Ph III recruiting: 1
Growth YoY: —
Industry share: 12%
Top sponsor: City of Hope Medical Center
Termination share: 32.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (14)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05711628	A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma	withdrawn	Phase 3	0	National Cancer Institute (NCI)NIH	0	Mar 20, 2024	clinicaltrials
NCT04952584	Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas	withdrawn	Phase 1	0	Baylor College of MedicineOTHER	1	Sep 7, 2023